GSK’s Synflorix: closer to a different marketplace?

LONDON, UK----28th January 2009----ExpertREACT. Recently the EU Committee For Medicinal Products for Human Use (CHMP) adopted a positive opinion to recommend a marketing authorisation for GSK’s new pneumococcal vaccine, Synflorix. The vaccine will compete in a fiercely competitive market dominated by Wyeth (PCV-7). With the recent Pfizer news, GSK are no doubt hoping the acquisition may affect an optimum PCV-13 launch. They also have longer-terms plans for pneumococcal vaccines

***NOTE*** This article is available for ExpertREACT subscribers only. Please visit www.vaccine-analytics/products-expertreact

References:


7) Vaccine Pipeline Review (CAT No: VAVS014), October 2008. Published by VacZine Analytics

A printable version of this article can be requested at info@vacZine-analytics.com. For more information about VacZine Analytics products and services please visit www.vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is a new strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new

© 2009 VacZine Analytics. All rights reserved.